[{"indications": "Indications\u00a0\n(From 8.3.2 Progestogens: British National Formulary)\n8.3.2 Progestogens", "name": "MEGESTROL ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.2 Progestogens"], "cautions": "Cautions\u00a0see under Medroxyprogesterone acetate (section\r\n6.4.1.2) and notes above; interactions: Appendix 1 (progestogens)", "side-effects": "Side-effects\u00a0see under Medroxyprogesterone acetate (section\r\n6.4.1.2) and notes above; also reported vomiting, carpal tunnel syndrome, Cushing\u2019s syndrome, and tumour\r\nflare (with or without hypercalcaemia)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4812.htm", "doses": ["Breast cancer, 160\u00a0mg once daily"], "pregnancy": "Pregnancy\u00a0avoid; reversible feminisation of male fetuses reported\r\nin animal studies; risk of hypospadias in male fetuses\r\nand masculinisation of female fetuses"}]